Published in New England Journal of Medicine · View the paper (DOI)
A large-scale randomized clinical trial confirms the safety of three Ebola vaccine regimens, inducing an immune response that persists for up to 12 months. The study suggests that vaccines can be a crucial tool in fighting the spread of the disease in sub-Saharan African countries.
Coverage from 2 institutions
- Trial on safety and immunogenicity of Ebola vaccines yields promising results INSERM (Institut national de la santé et de la recherche médicale) · Dec 14, 2022 · first to report
- Ebola vaccine regimens safe, immunogenic in adults and children NIH/National Institute of Allergy and Infectious Diseases · Dec 14, 2022